Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%

Healthcare

Page 96
  1. Nov 24, 2025 · 18:59 · SPLY

    Safe Supply obtains exclusive Canadian GLP-1 rights

    Safe Supply obtains exclusive Canadian GLP-1 rights

    01
  2. Nov 24, 2025 · 16:38 · TLT

    Theralase arranges minimum $4.5M private placement

    Theralase arranges minimum $4.5M private placement

    02
  3. Nov 24, 2025 · 16:23 · BHC

    Bausch Health launches $1.6-billion note exchange offer

    Bausch Health launches $1.6-billion note exchange offer

    03
  4. Nov 24, 2025 · 16:01 · INNO

    Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats

    Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats

    04
  5. Nov 24, 2025 · 15:19 · PREV

    CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)

    CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)

    05
  6. Nov 24, 2025 · 12:44 · RKV

    Rakovina talks ATR/mTOR dual inhibitor preclinical data

    Rakovina talks ATR/mTOR dual inhibitor preclinical data

    06
  7. Nov 24, 2025 · 09:05 · SPLY

    Safe Supply Secures Exclusive Canadian Rights to Healthy Sprays' Proprietary GLP-1 Delivery Technology; Announces Non-Brokered Private Placement

    Safe Supply Secures Exclusive Canadian Rights to Healthy Sprays' Proprietary GLP-1 Delivery Technology; Announces Non-Brokered Private Placement

    07
  8. Nov 24, 2025 · 09:01 · TTI

    Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

    Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

    08
  9. Nov 24, 2025 · 07:06 · NGEN

    NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

    NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

    09
  10. Nov 24, 2025 · 07:05 · BHC

    Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

    Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

    10
  11. Nov 24, 2025 · 07:02 · TLT

    Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    11
  12. Nov 24, 2025 · 07:02 · NGEN

    NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

    NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

    12
  13. Nov 24, 2025 · 06:00 · RKV

    Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

    Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

    13
  14. Nov 24, 2025 · 04:00 · RKV

    Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

    Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

    14
← Newer Older →